Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 27624958.
- Also identified by PMC identifier 5146720.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
Medical subject headings
- Azabicyclo Compounds
- Carbapenem-Resistant Enterobacteriaceae
- Ceftazidime
- Enterobacteriaceae Infections
- beta-Lactamase Inhibitors